Mauro Magnani mainly focuses on Immunology, Internal medicine, Cancer, Molecular biology and Red blood cell. Mauro Magnani has included themes like Clinical trial, Acquired immunodeficiency syndrome and Disease in his Immunology study. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Oncology.
His Cancer research is multidisciplinary, incorporating elements of Immunohistochemistry, Allele, Genotype and CDH1. His Molecular biology research incorporates themes from Polymerase chain reaction and Cell biology. Mauro Magnani has researched Red blood cell in several fields, including Blood cell, Endocrinology, Red Cell and In vivo.
His primary areas of investigation include Biochemistry, Molecular biology, Internal medicine, Immunology and Hexokinase. His works in Enzyme, Red blood cell, Glutathione, Affinity chromatography and Ubiquitin are all subjects of inquiry into Biochemistry. His study looks at the intersection of Internal medicine and topics like Oncology with Chemotherapy.
The study incorporates disciplines such as Pharmacology and Virology in addition to Immunology. His work carried out in the field of Virology brings together such families of science as In vitro and Antibody. Mauro Magnani combines subjects such as Chromatography and Isozyme with his study of Hexokinase.
Internal medicine, Cell biology, Cancer research, In vivo and Virology are his primary areas of study. A large part of his Internal medicine studies is devoted to Colorectal cancer. His research integrates issues of Transcription factor, Immune system and Glutathione in his study of Cell biology.
His Immune system study necessitates a more in-depth grasp of Immunology. His studies deal with areas such as Pharmacology and Enzyme as well as In vivo. His studies in Virology integrate themes in fields like Leishmania infantum and Leishmania.
The scientist’s investigation covers issues in Immunology, Cell biology, Pharmacology, Immune system and In vivo. His Immunology study combines topics in areas such as In vitro and Virology. The various areas that he examines in his Cell biology study include Cell, Glutathione and Macrophage.
His biological study spans a wide range of topics, including Phenylalanine ammonia-lyase, Oncology, Enzyme replacement therapy, Neutropenia and Colorectal cancer. His Immune system study integrates concerns from other disciplines, such as Antibody, Viral load and Vaccination. His In vivo study incorporates themes from Pharmacokinetics, Cytotoxic T cell, Cancer research and Drug delivery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis;A Ruzzo;C Cremolini;B Vincenzi.
British Journal of Cancer (2009)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis;Luca Pollina;Irene Stasi;Annamaria Ruzzo.
Journal of Clinical Oncology (2009)
Simultaneous extraction and reverse-phase high-performance liquid chromatographic determination of adenine and pyridine nucleotides in human red blood cells.
Vilberto Stocchi;Luigi Cucchiarini;Mauro Magnani;Laura Chiarantini.
Analytical Biochemistry (1985)
Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy
Annamaria Ruzzo;Francesco Graziano;Fotios Loupakis;Eliana Rulli.
Journal of Clinical Oncology (2007)
Development of a real-time PCR assay for rapid detection and quantification of Alexandrium minutum (a Dinoflagellate).
Applied and Environmental Microbiology (2004)
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.
Daniele Santini;Fotios Loupakis;Bruno Vincenzi;Irene Floriani.
Loss of CD127 Expression Defines an Expansion of Effector CD8+ T Cells in HIV-Infected Individuals
Mirko Paiardini;Barbara Cervasi;Barbara Cervasi;Helmut Albrecht;Alagarraju Muthukumar.
Journal of Immunology (2005)
Cell-based drug delivery.
F. Pierigè;S. Serafini;L. Rossi;M. Magnani.
Advanced Drug Delivery Reviews (2008)
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer.
Giuseppe Perrone;Pier Adelchi Ruffini;Vincenzo Catalano;Cathie Spino.
European Journal of Cancer (2008)
The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB).
M. Magnani;R. Crinelli;M. Bianchi;A. Antonelli.
Current Drug Targets (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: